Combining endocrine agents with chemotherapy: Which patients and what sequence?

Cancer

Volumn 112, Issue 3 SUPPL., 2008, Pages 718-722

  Pritchard, Kathleen I ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Chemotherapy; Endocrine therapy; Hormone therapy; Metastatic; Tamoxifen

Indexed keywords

ANTIMETABOLITE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; KI 67 ANTIGEN; MELPHALAN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; HUMAN; METASTASIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 38749116969     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23189     Document Type: Conference Paper

References (34)

1. Levine R, Lippman ME, Longo D, Cowan K. Effects of estrogen and tamoxifen on dihydrofolate reductase in gene-amplified methotrexate resistant human breast cancer cells. Proc Am Assoc Cancer Res. 1983;24:173.
2. Benz C, Moellekin B, Cadman E. RNA and estrogen receptor effects associated with tamoxifen-fluorouracil synergy in breast cancer. Proc Am Assoc Cancer Res. 1983;24:173.
3. Jordan VC, Tormey DC, Clifton K, et al. Treatment of rat mammary cancer by combinations of tamoxifen and cyclophosphamide. Proc Am Assoc Cancer Res. 1980;21:293.
4. Goldenberg GJ. The effect of diethylstilbestrol and tamoxifen on the cytocidal activity and uptake of melphalan (M) in human breast cancer cells in vitro [abstract]. Proc Am Soc Clin Oncol. 1983;2:22.
5. Bibby MC, Double JA, Mughal MA. Effects of nandrolone decanoate on the toxicity and antitumor action of CCNU and FU in murine tumors. Br J Cancer. 1981;44:572-577.
6. Oberfield RA, Cady B, Pazianos AG, et al. Adrenalectomyoophorectomy and combined chemotherapy for carcinoma of the breast with metastases. Surg Gynecol Obstet. 1979; 148:881-886.
7. Ahmann DL, O'Connell MJ, Hahn RG, Bisel HF, Lee RA, Edmonson JH. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med. 1977;297:356-360.
8. Australian and New Zealand Breast Cancer Trials Group. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol. 1986;4:186-193.
9. Bezwoda WR, Derman D, De Moor NG, Lange M, Levin J. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF. Cancer. 1982;50:2747-2750.
10. Cavalli F, Beer M, Martz G, et al. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Res. BMJ (Clin Res Ed). 1983;286:5-8.
11. Falkson G, Falkson HC, Glidewell O. Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study by Cancer and Leukemia Group B. Cancer. 1979;43:2215-2222.
12. Glick JH, Creech RH, Torri S, et al. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer. Cancer. 1980;45:735-741.
13. Kiang DT, Gay J, Goldman A, Kennedy BJ. A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med. 1985;313:1241-1246.
14. Kumar KS, Vogel CL, Moore MR, et al. Sequential versus concomitant chemo-hormonal therapy in breast cancer. Breast. 1982;8:2-7.
15. Rossof A, Gelman R, Creech RH. Randomized evaluation of combination chemotherapy vs observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women. Am J Clin Oncol. 1982;5:253-259.
16. Brunner KW, Sonntag RW, Alberto P, et al. Combined chemo and hormonal therapy in advanced breast cancer. Cancer. 1977;39:2923-2933.
17. Cocconi G, DeLisi V, Boni C, et al. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer. 1983;51:581-588.
18. Gercovich FG, Morgenfeld EL, Rivarola EG, et al. Chemotherapy (CT) vs chemohormonal therapy (CT+HT) for postmenopausal patients (PT) with advanced breast cancer. Proc Am Assoc Cancer Res. 1988;29:197.
19. Kardinal CG, Perry MC, Weinberg V, et al. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study. Breast Cancer Res Treat. 1983;3:365-372.
20. Kardinal CG, Perry MC, Korzun AH, et al. Response to chemotherapy or chemoendocrine therapy in patients with advanced breast cancer previously treated with adjuvant chemotherapy. Breast Cancer Res Treat. 1985;6:185.
21. Krook JE, Ingle JN, Greer SJ, et al. Randomized clinical trial of cyclophosphamide 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. Cancer Treat Rep. 1985;69:355-361.
22. Mouridsen HT, Rose C, Engelsman E, et al. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. Eur J Cancer Clin Oncol. 1985;21:291-299.
23. Rubens RD, Begent R, Knight RK. Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer. 1978;42:1680-1686.
24. Tormey DC, Falkson G, Crowley J, et al. Dibromodulcitol and Adriamycin plus or minus tamoxifen in advanced breast cancer. Am J Clin Oncol. 1982;5:33-39.
25. Viladiu P, Alonso M, Avella A. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial. Cancer. 1985;56:2745-2750.
26. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 1986;4:459-471.
27. Pritchard KI, Paterson AH, Fine S, et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol. 1997;15:2302-2301.
28. Sertoli MR, Pronzato P, Amoroso D, et al. A randomized study of concurrent versus sequential chemotherapy and tamoxifen in stage II breast cancer [abstract]. Proc Am Soc Clin Oncol. 1991;10:14a.
29. Sertoli MR, Pronzato P, Ventorini M, et al. A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21:46a.
30. Pico C, Martin M, Jara C. Epirubicin-cyclophosphamide chemotherapy plus tamoxifen administered concurrent versus sequential: randomized phase III trial in postmenopausal node-positive breast cancer patients. GEICAM 9401 study [abstract]. Proc Am Soc Clin Oncol. 2002; 21:37a.
31. Pico C, Martin M, Jara C, et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol. 2004;15:79-87.
32. Albain K, Green S, Ravdin P, et al. Overall survival after cyclophosphamide, Adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal receptor (+), node (+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100) [abstract]. Proc Am Soc Clin Oncol. 2001; 20:94a.
33. Albain K, Green S, Osborne K, et al. Tamoxifen (T) versus cyclophosphamide, Adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal receptor (+), or node (+) breast cancer: a Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100) [abstract]. Proc Am Soc Clin Oncol. 1997;16:128a.
34. Albain K, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100 (SWOG-8814) [abstract]. Proc Am Soc Clin Oncol. 2002;21:37a.